USA flag logo/image

An Official Website of the United States Government

Novel Therapy to Treat Otitis Media

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
89264
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
HD058400
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOMEDICAL DEVELOPMENT CORPORATION
A152 ASTeCC Building Lexington, KY 40506-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Novel Therapy to Treat Otitis Media
Agency: HHS
Contract: 1R43HD058400-01
Award Amount: $107,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Otitis media is a common childhood disease with annual direct costs estimated to exceed 3 billion. Otitis media is the most frequent cause of pediatric practitioner visits and results in more than 20 million antibiotic prescriptions annually. However, the pathogens associated with otitis media have become increasingly resistant to the prescribed antibiotics. Molecular examination of chronic cases of otitis media demonstrates the presence of bacteria encased in complex m icrobial communities known as biofilms. Antibiotic agents have proven to be ineffective against biofilm infections seen in chronic otitis media. A therapy that is effective against both chronic and acute otitis media, that does not induce microbial resista nce, and that is effective against biofilms would be highly beneficial and have significant commercial potential. The goal of this project is to develop a unique, safe, and efficacious treatment for both acute and chronic otitis media. Prototype formulatio ns will be tested in vitro and in an animal model of otitis media. The Specific Aims of the proposal are: Specific Aim 1. Formulate Iocide for use in treating otitis media Specific Aim 2. Evaluate Iocide for antibacterial activity on planktonic and biofilm bacteria in vitro Specific Aim 3. Demonstrate the effectiveness and safety of Iocide in an animal model of otitis media. PUBLIC HEALTH RELEVANCE: Otitis media is a common childhood disease with annual direct costs estimated to exceed 3 billion. Otitis me dia is the most frequent cause of pediatric practitioner visits and results in more than 20 million antibiotic prescriptions annually. Consequent to the widespread use of antibiotics, the pathogens associated otitis media have become increasingly resistant to antibiotic therapy.

Principal Investigator:

Business Contact:


gsiegel@biodevcorp.com
Small Business Information at Submission:

BIOMEDICAL DEVELOPMENT CORPORATION
BIOMEDICAL DEVELOPMENT CORP 500 SANDAU, STE 200 SAN ANTONIO, TX 78216

EIN/Tax ID: 742330067
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No